Literature DB >> 35312904

Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group.

Kenichiro Asano1, Yoji Yamashita2, Takahiro Ono3, Manabu Natsumeda4, Takaaki Beppu5, Kenichiro Matsuda6, Masahiro Ichikawa7, Masayuki Kanamori8, Masashi Matsuzaka9, Akira Kurose10, Toshio Fumoto11, Kiyoshi Saito7,12, Yukihiko Sonoda6, Kuniaki Ogasawara5, Yukihiko Fujii4, Hiroaki Shimizu3, Hiroki Ohkuma11,13, Chifumi Kitanaka14, Takamasa Kayama15, Teiji Tominaga8.   

Abstract

Clinicopathological risk factors for a poor prognosis were investigated in elderly patients with malignant lymphoma of the central nervous system. A total of 82 pathologically confirmed, CD20-positive, diffuse large B-cell lymphoma patients aged 71 years or older who underwent therapeutic intervention in the Tohoku and Niigata area in Japan were retrospectively reviewed. A univariate analysis was performed by the log-rank test using the Kaplan-Meier method. A Cox proportional hazards model was used for multivariate analysis of risk factors. Of the 82 patients, 39 were male and 43 were female, and their median age at onset was 75 years. At the end of the study, there were 34 relapse-free patients (41.5%), 48 relapse cases (58.5%), median progression-free survival was 18 months, and median overall survival (OS) was 26 months; there were 41 deaths and 41 survivors. Multivariate analysis of median OS showed that Karnofsky Performance Status less than 60% 3 months after treatment (p = 0.022, hazard ratio (HR) = 2.591) was the clinical risk factor, and double expressor lymphoma (p = 0.004, HR = 3.163), expression of programmed death-ligand 1 in tumor infiltrating lymphocytes or tumor-associated macrophages (p < 0.001, HR = 5.455), and Epstein-Barr virus infection (p = 0.031, HR = 5.304) were the pathological risk factors.
© 2022. The Author(s) under exclusive licence to The Japan Society of Brain Tumor Pathology.

Entities:  

Keywords:  Diffuse large B-cell lymphoma; Double expressor lymphoma; Elderly patients with PCNSL; Epstein–Barr virus; Programmed death-ligand 1

Year:  2022        PMID: 35312904     DOI: 10.1007/s10014-022-00427-4

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  47 in total

1.  Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.

Authors:  Lauren E Abrey; Leah Ben-Porat; Katherine S Panageas; Joachim Yahalom; Brian Berkey; Walter Curran; Christopher Schultz; Steven Leibel; Diana Nelson; Minesh Mehta; Lisa M DeAngelis
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

2.  A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases.

Authors:  Sophie Camilleri-Broët; Emmanuelle Crinière; Philippe Broët; Vincent Delwail; Karima Mokhtari; Anne Moreau; Michèle Kujas; Martine Raphaël; Wafae Iraqi; Catherine Sautès-Fridman; Philippe Colombat; Khê Hoang-Xuan; Antoine Martin
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  GCB-type is a favorable prognostic factor in primary CNS diffuse large B-cell lymphomas.

Authors:  Chelsea Marcus; Georgios A Maragkos; Ron L Alterman; Erik Uhlmann; German Pihan; Hemant Varma
Journal:  J Clin Neurosci       Date:  2020-12-16       Impact factor: 1.961

4.  Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?

Authors:  B W Corn; S M Marcus; A Topham; W Hauck; W J Curran
Journal:  Cancer       Date:  1997-06-15       Impact factor: 6.860

Review 5.  Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.

Authors:  Kensuke Tateishi; Yohei Miyake; Taishi Nakamura; Tetsuya Yamamoto
Journal:  Brain Tumor Pathol       Date:  2021-07-13       Impact factor: 3.298

Review 6.  Management of elderly patients with primary central nervous system lymphoma.

Authors:  Mariza Daras; Lisa M DeAngelis
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081

7.  Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.

Authors:  Andrés J M Ferreri; Jean-Yves Blay; Michele Reni; Felice Pasini; Michele Spina; Achille Ambrosetti; Antonello Calderoni; Andrea Rossi; Vittorio Vavassori; Annarita Conconi; Liliana Devizzi; Françoise Berger; Maurilio Ponzoni; Bettina Borisch; Marianne Tinguely; Michele Cerati; Mario Milani; Enrico Orvieto; Juvenal Sanchez; Christine Chevreau; Stefania Dell'Oro; Emanuele Zucca; Franco Cavalli
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

8.  Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.

Authors:  Stefan Hatzl; Florian Posch; Alexander Deutsch; Christine Beham-Schmid; Herbert Stöger; Hildegard Greinix; Martin Pichler; Peter Neumeister; Katharina T Prochazka
Journal:  Hematol Oncol       Date:  2020-02-26       Impact factor: 5.271

9.  Treatment outcome and prognostic factors in PCNSL.

Authors:  Pimjai Niparuck; Paisarn Boonsakan; Taksayut Sutthippingkiat; Sulada Pukiat; Pichika Chantrathammachart; Sithakom Phusanti; Kochawan Boonyawat; Teeraya Puavilai; Pantep Angchaisuksiri; Artit Ungkanont; Suporn Chuncharunee; Vichai Atichartakarn
Journal:  Diagn Pathol       Date:  2019-06-13       Impact factor: 2.644

10.  PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.

Authors:  Motomasa Furuse; Hiroko Kuwabara; Naokado Ikeda; Yasuhiko Hattori; Tomotsugu Ichikawa; Naoki Kagawa; Kenichiro Kikuta; Sho Tamai; Mitsutoshi Nakada; Toshihiko Wakabayashi; Masahiko Wanibuchi; Toshihiko Kuroiwa; Yoshinobu Hirose; Shin-Ichi Miyatake
Journal:  BMC Cancer       Date:  2020-04-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.